Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to determine changes in kidney function during and after critical illness, comparing conventional creatinine based methods with the gold standard to accurately establish the presence of new or worsened chronic kidney disease. In addition, investigators will assess the confounding effect of muscle wasting on the conventional assessment of kidney function and investigate the information that measures of kidney function may contribute to the assessment of musculoskeletal health after critical illness.
More people than ever are surviving life-threatening illnesses such as major trauma. However, until now doctors and researchers have focused more on improving short term survival than on the serious, long-term complications experienced by survivors of critical illness. In response, the National Institute for Health and Care Excellence (NICE) and patient-clinician partnerships such as the James Lind Alliance, have now prioritised research into the diagnosis, follow-up and treatment of critical care survivors.
Development of chronic kidney disease and persistent muscle weakness are two commonly encountered complications which significantly impact long-term health and wellbeing after critical illness. Worsening of kidney function strongly predisposes to development of heart disease, premature death or need for long-term dialysis. Similarly, the muscle wasting experienced by almost all survivors of critical illness can result in persistent, life changing limitations to daily living, inability to work and decreased quality of life. Importantly, the human and economic consequences of critical illness may be particularly profound in major trauma victims who are often young and previously healthy. In this project, investigators will aim to simultaneously measure changes in kidney function and muscle mass after critical illness allowing researchers to understand how these processes interact in affecting longer-term patient outcomes.
The investigators will recruit 62 patients, 31 admitted to intensive care after major trauma and 31 admitted for other reasons. Complementary methods will be used to accurately monitor muscle mass and kidney function. Six months after discharge from hospital, patient's ability to manage their daily activities and quality of life will be assessed alongside measurements of muscle mass, strength and kidney function. The study will be performed at the Royal London Hospital, an internationally renowned centre for critical care and trauma research.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| General ICU admissions | Non- major trauma ICU admission Exposure to significant period of critical illness |
| |
| Major Trauma admissions | Exposure to Major Trauma Exposure to significant period of critical illness |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exposure of significant critical illness | Other | Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in estimated Glomerular Filtration Rate (eGFR) between creatinine- and cystatin C-based estimates. | At 7 days after ICU discharge. |
| Measure | Description | Time Frame |
|---|---|---|
| Rectus Femoris muscle wasting | Change in cross sectional area of Rectus Femoris assessed via ultrasound | From ICU admission (day 1 to 10) and 7 days and 6 months after ICU discharge. Time period up to and including 18 months from recruitment. |
| Diagnosis of a negative Nitrogen Balance |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients admitted to critical care.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal London Hospital | London | E11BB | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28614196 | Background | Ravn B, Prowle JR, Martensson J, Martling CR, Bell M. Superiority of Serum Cystatin C Over Creatinine in Prediction of Long-Term Prognosis at Discharge From ICU. Crit Care Med. 2017 Sep;45(9):e932-e940. doi: 10.1097/CCM.0000000000002537. | |
| 37256861 | Derived | Haines RW, Fowler AJ, Liang K, Pearse RM, Larsson AO, Puthucheary Z, Prowle JR. Comparison of Cystatin C and Creatinine in the Assessment of Measured Kidney Function during Critical Illness. Clin J Am Soc Nephrol. 2023 Aug 1;18(8):997-1005. doi: 10.2215/CJN.0000000000000203. Epub 2023 May 31. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Quadriceps muscle tissue, blood and urine
Serum and urinary urea measurements aggregated as net nitrogen balance. |
| From ICU admission (day 1 to 10) and 7 days after ICU discharge. |
| Respiratory muscle wasting | Change in cross sectional area of intercostal muscle, change in diaphragm thickness | From ICU admission (day 1 to 10) and 7 days and 6 months after ICU discharge. |
| Loss of muscle quality | Change in Rectus femoris muscle echogenecity | From ICU admission (day 1 to 10) and 7 days and 6 months after ICU discharge. |
| Loss of functional capacity | Change in Functional Independence Measure | 7 days and 6 months after ICU discharge. |
| Diagnosis of Anxiety of Depression | Change in Hospital Anxiety and Depression Scale | 7 days and 6 months after ICU discharge. |
| Diagnosis of Sarcopaenia | Assessed using bioelectrical impedance analysis, change in cross sectional area of abdominal skeletal muscle, | From ICU admission (day 1 to 10) and 7 days and 6 months after ICU discharge. |
| Diagnosis of Intensive care unit acquired weakness | Assessed using MRC Sum score | From ICU admission (day 1 to 10) and 7 days and 6 months after ICU discharge. |
| Diagnosis of Intensive care unit acquired weakness | Assessed using hand grip strength. | From ICU admission (day 1 to 10) and 7 days and 6 months after ICU discharge. |
| Change in quality of life | Change in Euroqol 5d 5L (European quality of life group, quality of life instrument version 5D5L) | pre-admission baseline then 7 days and 6 months after ICU discharge. |
| Change in walking capacity | Change in Six minute walk test | 7 days and 6 months after ICU discharge. |
| Diagnosis of chronic kidney disease | Diagnosis using creatinine clearance, iohexol and serum creatinine derived eGFR | 6 months after ICU discharge |
| Diagnosis of non-recovery of eGFR to baseline | Diagnosis using creatinine clearance, iohexol and serum creatinine derived eGFR | From ICU admission (day 3 to 10) and 7 days after ICU discharge. |
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| D058186 | Acute Kidney Injury |
| D009133 | Muscular Atrophy |
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D012816 | Signs and Symptoms |
| D002908 | Chronic Disease |
Not provided
Not provided